openPR Logo
Press release

Rare Inflammatory Disease Treatment Market Comprehensive Analysis 2017-2026 | Key Players are Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Inc.

02-08-2019 09:31 AM CET | Health & Medicine

Press release from: Future Market Insights

Rare Inflammatory Disease Treatment Market Comprehensive

With mounting instances of genetic diseases, demand for therapeutic measures have witnessed a hike, as no effective procedures exist that provide effective treatment of genetic or rare inflammatory diseases. Chromosomal changes primarily influence prevalence of these diseases. In a bid to curtail the disease prevalence, several pharmaceutical industries have been taking efforts to make advancements in relevant drugs as well as therapeutic methods. For example, new treatment options are being developed by researchers for geriatric and pediatric patients suffering from Still’s disease, which is a rare disease linked with the inflammation of joints.

Doctors are stepping up their efforts by creating awareness among the patients with regard to benefits of anti-inflammatory drugs, which have been deemed effective in the prevention and control of rare inflammatory diseases. Currently, there is rapid increase in the demand for authorized effective treatments of the rare inflammatory diseases. The OOPD (Office of Orphan Products Development) has been offering incentives to drug companies, supporting the development of treatment methods for these diseases. National Institutes of Health (NIH) are providing immense support for improving patients’ health, by focusing mainly on the development of new treatment methods. Collaborative projects are being initiated by NIH in order to examine the common causes and effects of related diseases.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6428

Significant findings from report show that the global market for rare inflammatory disease treatment will increase at an assessed 4.4% CAGR during the forecast period, 2017-2026. The report also anticipates that by 2026-end, rare inflammatory disease treatment worth nearly US$ 15,960.8Mn will be witnessed across the globe.

Increasing Inflammatory & Autoimmune Diseases to Create Opportunities for New Therapies

Several group of scientists have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases, which in turn is creating new ways of development for therapies. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.

Moreover, the occurrence of inflammatory and autoimmune diseases is increasing on a rapid pace. Globally, an approximate number of 125 million populace are affected by psoriasis and around 100 million by rheumatoid arthritis annually. The presence of inflammatory bowel infections such as ulcerative colitis and Crohn’s disease is increasing at an alarming rate in formerly unaffected fragments of the world.

Request customized copy of report @ https://www.futuremarketinsights.com/customization-available/rep-gb-6428

Key Takeaways from Rare Inflammatory Disease Treatment Market Report for Estimated Period, 2017-2026

In terms of revenue, North America will remain the largest market for rare inflammatory disease treatment market, closely followed by Europe. Nearly half value share of the market is held by rare inflammatory disease treatment sales in North America and Europe collectively. APEJ will also bolt onto a largest market revenue share, by registering a relatively faster expansion than Europe in the market through 2026.

On the basis of indication, ulcerative colitis are likely to remain considerably larger than that of the other segments.

The lion’s share in the global market for rare inflammatory disease treatment is contributed by biologics segment.

Oral care & Hospital Pharmacies will observe fastest growth during the forecast period.

Key market players outlined by the report is inclusive of Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Inc., Novartis AG, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, and Swedish Orphan Biovitrum AB.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Blog: http://www.marketresearchblog.org/

FMI Blog: https://www.fmiblog.com/

Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rare Inflammatory Disease Treatment Market Comprehensive Analysis 2017-2026 | Key Players are Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Inc. here

News-ID: 1571800 • Views:

More Releases from Future Market Insights

Tire Changing Machines Market Growth Driven by Automation and Aftermarket Expansion
Tire Changing Machines Market Growth Driven by Automation and Aftermarket Expans …
The tire changing machines market is estimated at USD 575.3 million in 2025 and expected to reach USD 893.4 million by 2035, reflecting a CAGR of 4.5%. While the growth rate is moderate, the expansion is steady, supported by a surge in global vehicle ownership, expansion of automotive aftermarkets, and increasing adoption of automation technologies across workshops and service centers. This market's cost structure is shaped by raw materials, precision manufacturing,
Particulate Matter Monitoring Market to Reach USD 4.4 Billion by 2035 Driven by Tech and Regulation
Particulate Matter Monitoring Market to Reach USD 4.4 Billion by 2035 Driven by …
The global particulate matter monitoring market is on track to grow at an impressive rate, reaching USD 4.4 billion by 2035 from USD 1.4 billion in 2025. This robust compound annual growth rate of 12.0% reflects rising environmental awareness, tougher regulations, and the surge of new technologies enabling more accurate, real-time monitoring solutions. Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-25736 Rising Demand Across Industries and
Smart Agriculture Market to Reach USD 72.1 Billion by 2035 with Strong Growth Driven by Precision Farming
Smart Agriculture Market to Reach USD 72.1 Billion by 2035 with Strong Growth Dr …
The global smart agriculture market is on a remarkable growth trajectory, projected to expand from USD 23.2 billion in 2025 to USD 72.1 billion by 2035, achieving a robust CAGR of 12.0%. The expansion reflects the growing demand for precision farming, sensor-based monitoring systems, and automation-driven crop management practices. Intermediate milestones highlight this upward trend, with the market anticipated to hit USD 36.5 billion by 2029 and USD 51.3 billion
Hydrogen Fluoride Gas Detection Market Poised for Steady Growth, Reaching USD 1083.4 Million by 2035
Hydrogen Fluoride Gas Detection Market Poised for Steady Growth, Reaching USD 10 …
The hydrogen fluoride gas detection market is on track for consistent growth, projected to increase from USD 652.6 million in 2025 to USD 1083.4 million by 2035, registering a compound annual growth rate (CAGR) of 5.2%. Year-on-year expansion highlights a steady trajectory, with the market estimated to reach USD 799.3 million by 2029 and USD 930.5 million by 2032. This momentum is fueled by rising demand for safety monitoring in

All 5 Releases


More Releases for Inflammatory

Inflammatory Myositis Market Massive Growth opportunity Ahead
Introduction Inflammatory myositis is a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive muscle weakness, fatigue, and functional disability. The spectrum includes polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and overlap syndromes. These disorders can also involve other organs, most notably the lungs (interstitial lung disease), skin, heart, and joints, complicating disease management. Historically, corticosteroids and conventional immunosuppressants have formed
Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflamma …
The Anti-Inflammatory Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Anti-Inflammatory Therapeutics Market Size and Projected Growth Rate? The market size of anti-inflammatory therapeutics has shown a consistent growth in the past few years. The market is projected to expand from $114.71
Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflamma …
What market dynamics are playing a key role in accelerating the growth of the anti-inflammatory therapeutics market? As inflammatory bowel disease becomes more commonplace, it is predicted to encourage progress in the anti-inflammatory therapeutics market. Characterized as a long-term condition causing inflammation of the digestive tract, inflammatory bowel disease (IBD) is effectively managed with the usage of anti-inflammatory therapeutics. These treatments are central in the control of Crohn's disease via decreasing
Anti-Inflammatory Activity Enzyme Manufacturer | Pearlzyme Inc
Pearlzyme Inc. is a South Korean company that manufactures anti inflammatory activity enzymes. This anti-inflammatory activity enzyme boosts the animal's immune system against infection and increases milk lactation. Pearlzyme Inc. is committed to providing high-quality products and services to its customers. The company has a team of experienced scientists and engineers who are constantly working to develop new and innovative products. Pearlzyme Inc. is also committed to sustainable development and is
Inflammatory Bowel Disease Market: The Present and Future of Inflammatory Bowel …
Stratagem Market Insights have included the latest addition of a global market research report titled Inflammatory Bowel Disease Market tits expansive repository. The report studies primary and secondary research in order to analyze the data effectively. The market study further draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses, significant
Rising incidences of chronic inflammatory and autoimmune diseases has increased …
According to a new report published by apacmarket.com, titled, Anti-inflammatory Therapeutics Asia-Pacific Market Research Report, 2014-2020, the Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% during the period of 2015-2020. The arthritis segment would continue to lead the Asia Pacific anti-inflammatory therapeutics market through 2020. China anti-inflammatory therapeutics market is forecast to grow at the highest CAGR of 13.9% during the forecast period. Get the sample